Avery Dennison Corp

Avery Dennison shares have fallen 10.1% over the past six months to $163.83, underperforming the S&P 500's 11.4% gain, prompting a cautious outlook from analysts. The company's organic revenue grew just 2% annually over the last two years, signaling weak demand in its core business. Wall Street forecasts only 3.7% revenue growth over the next 12 months, near its five-year annualized rate of 4.3%, while earnings per share expanded at a similarly modest 4.3% annual pace. The stock now trades at 15.3 times forward earnings, a valuation deemed reasonable but not compelling, with analysts suggesting more exciting opportunities elsewhere.

StockStory highlights Elevance Health as a cash-producing stock with exciting potential, while recommending investors sell RingCentral and Avery Dennison. Elevance Health, one of America's largest health insurers serving approximately 47 million medical members, has achieved 9.9% annualized sales growth over the last five years on a revenue base of $198.3 billion, and its market-beating returns on capital demonstrate effective investment. RingCentral, with a trailing 12-month free cash flow margin of 21.2%, faces underwhelming average billings growth of 5.2% and estimated sales growth of 4.5% for the next 12 months, implying slowing demand. Avery Dennison, with a trailing 12-month free cash flow margin of 9.3%, has seen organic revenue growth fall short of benchmarks and earnings per share grow only 4.3% annually over the last five years, lagging peers.